NRX:CC News and Press, NurExone Biologic Inc. From 09/28/23

TORONTO and HAIFA, Israel, Sept. 28, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal ...

VANCOUVER, BC / ACCESSWIRE / September 13, 2023 / The Watchlist by The Market Herald has announced the release of new interviews with NurExone Biologic and SuperBuzz discussing their latest news. The Watchlist by The Market Herald provides investors with a quick snapshot of what they need to kn...

The FDA’s response indicated that the planned toxicity study strategy is acceptable under FDA guidelines and large-scale animal studies will not be required. The completed Pre-IND meeting with the FDA is expected to expedite NurExone’s regulatory process to initiate Phase ...

TORONTO and HAIFA, Israel, Sept. 06, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal ...

Completed the first tranche of a non-brokered private placement offering of units for gross proceeds of approximately CAD$1.3 million to extend cash runway into 2024 Strengthened the Board of Directors through the appointment of Dr. Gadi Riesenfeld, Former President of Pharmos Corporation...

Not for distribution to United States newswire services or for dissemination in the United States TORONTO and TEL AVIV, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (“ NurExone ” or the “ Company ”) annou...

TORONTO and TEL AVIV, Israel, July 20, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (“NurExone” or the “Company”) is pleased to announce significant advancements in extracellular vesicles (EVs) functionality. Leveraging its proprietary...

Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - July 7, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (" NurExone " or the " Company ") is pleased to announce that, effective July 6, 2023, Dr. Gadi Riesenfeld has been appointed to the board of directors of the Company rep...

TORONTO and TEL AVIV, Israel, June 22, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX) (FSE: J90) (NRX.V), is pleased to report positive imaging results from an internal preclinical study of its investigational drug ExoPTEN. The image analysis and measure...

MUNICH, Germany and TEL AVIV, Israel, June 01, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (the "Company" or "NurExone") (TSXV: NRX) (FSE: J90), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, is pleas...